<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01412216</url>
  </required_header>
  <id_info>
    <org_study_id>Sedentarism</org_study_id>
    <nct_id>NCT01412216</nct_id>
  </id_info>
  <brief_title>The Effects of Sedentarism on Vascular Function, Inflammation, and Insulin Resistance</brief_title>
  <acronym>Bedrest</acronym>
  <official_title>The Effects of Sedentarism on Vascular Function, Inflammation, and Insulin Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <brief_summary>
    <textblock>
      The purpose of this study are twofold:&#xD;
&#xD;
        1. To understand the effects of physical inactivity (sedentarism) on vascular function,&#xD;
           insulin resistance and inflammation;&#xD;
&#xD;
        2. To assess the role of a dietary intervention (fish oil) in counteracting the effects of&#xD;
           physical inactivity on vascular function and inflammation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Funding Depleted.&#xD;
  </why_stopped>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial Function</measure>
    <time_frame>5 days</time_frame>
    <description>Flow-mediated, brachial artery vasodilation (FMD)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin Resistance</measure>
    <time_frame>5 days</time_frame>
    <description>The homeostatic model assessment (HOMA) method used to quantify insulin resistance (HOMA-IR)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Endothelial Dysfunction</condition>
  <condition>Insulin Resistance</condition>
  <condition>Metabolic Syndrome</condition>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Fish Oil (Omega-3 Fatty Acids)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High-dose, short-duration dietary omega-3 fatty acids supplementation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo control</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish Oil (Omega-3 Fatty Acids)</intervention_name>
    <description>fish oil-4.4gm/day x 5 days</description>
    <arm_group_label>Fish Oil (Omega-3 Fatty Acids)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish Oil (Omega-3 Fatty Acids)</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy subjects: Subjects must be free from any acute, chronic or debilitating&#xD;
             medical conditions. Healthy status will be established on the basis of clinical&#xD;
             history, electrocardiogram, clinical biochemical screening tests of blood and urine, a&#xD;
             physical examination, and where necessary a chest radiograph.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any active acute or chronic medical problem: Any subject with symptoms of active&#xD;
             illness (e.g., fever, leukocytosis, hypertension) will be excluded from study. The&#xD;
             exclusion criteria will also include history or evidence for psychiatric disorders,&#xD;
             hypertension, diabetes, coronary artery disease (CAD), renal insufficiency, thyroid&#xD;
             disease, alcohol or drug abuse, viral hepatitis, deep venous thrombosis or anemia.&#xD;
             Individuals with a history of psychiatric illnesses or psychiatric disorders will also&#xD;
             be excluded, such as alcoholism, drug dependency including dependency on tobacco,&#xD;
             major mood disorders such as major depression and manic depressive illness,&#xD;
             schizophrenic disorders, anxiety disorders including panic disorder, generalized&#xD;
             anxiety disorder, post traumatic stress disorder, obsessive compulsive disorder,&#xD;
             agoraphobia, claustrophobia, paranoid personality disorder, schizoid personality&#xD;
             disorder, schizotypal personality disorder, borderline personality disorder, and&#xD;
             antisocial personality disorder. In addition, potential subjects with a first order&#xD;
             relative with a history of major depressive illness, manic depressive illness,&#xD;
             schizophrenia, agoraphobia or panic disorder will also be excluded from entry to this&#xD;
             study. Finally, individuals who are unaware of specific psychiatric diagnoses who have&#xD;
             a history of having been treated with antidepressant, neuroleptic medications or major&#xD;
             tranquilizers will be excluded from study. However, a personal history of limited&#xD;
             prior counseling or psychotherapy (e.g., for adjustment reactions) will not&#xD;
             necessarily be exclusionary.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marlene Grenon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <study_first_submitted>August 5, 2011</study_first_submitted>
  <study_first_submitted_qc>August 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2011</study_first_posted>
  <last_update_submitted>November 6, 2013</last_update_submitted>
  <last_update_submitted_qc>November 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sedentarism</keyword>
  <keyword>Physical inactivity</keyword>
  <keyword>Fish oil</keyword>
  <keyword>Omega-3 fatty acids</keyword>
  <keyword>Endothelial dysfunction</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Metabolic syndrome</keyword>
  <keyword>peripheral arterial disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

